Inclusion Criteria:

- Patients with AML who are not candidates for myelosuppressive chemotherapy or AML who
have relapsed disease or refractory to standard therapy and not likely to require
cytoreductive therapy within one month, or MDS subtypes RAEB, RAEB-T or CMML

- Patients with a wild type or mutated FLT3 documented within 14 days prior to start of
study who have not previously received a FLT3 inhibitor.

- Patients with a WHO performance status of 0 to 2 with a life expectancy of at least 3
months

Exclusion Criteria:

- Patients who had prior allergenic, syngeneic, or autologous bone marrow transplant or
stem cell transplant less than 2 months previously.

- Female patients who are pregnant or breast feeding or adults of childbearing age not
employing an effective method of birth control

- Concurrent severe and/or uncontrolled medical or psychiatric condition which may
interfere with the completion of the study

- Impairment of GI function or GI disease that may significant alter the absorption of
PKC412

- Patients who had more than 2 prior regimens for their current relapsed or current
primary refractory disease.

- Uncontrolled active infection

Other protocol-defined inclusion/exclusion criteria may apply